Navigation Links
Aware, Inc. Reports Third Quarter 2011 Financial Results
Date:10/25/2011

ements regarding future events and are subject to risks and uncertainties, such as estimates or projections of future revenue and earnings and the growth of the DSL test and diagnostics and biometrics markets. Aware wishes to caution you that there are factors that could cause actual results to differ materially from the results indicated by such statements.

General factors include, but are not limited to: our quarterly results are unpredictable and may fluctuate significantly; our business is subject to rapid technological change; we face intense competition from a wide range of competitors; our intellectual property is subject to limited protection; our business may be affected by our use of open source software; our business may be affected by government regulations; adverse economic conditions; and our ability to obtain or enforce patents could be affected by new laws, regulations or rules. DSL test and diagnostic factors include, but are not limited to: our DSL test and diagnostic businesses depend upon a limited number of customers; the success of our DSL test and diagnostics products businesses requires telephone companies to install DSL service in volume; our test and diagnostic hardware and software products could have quality problems; we depend on a single source contract manufacturer for the manufacture of our DSL hardware products; and we are dependent on single source suppliers for components in our DSL hardware products. Biometric factors include, but are not limited to: market acceptance of our biometric technologies and products; changes in contracting practices of government or law enforcement agencies; the failure of the biometrics market to experience continued growth; announcements or introductions of new technologies or products by our competitors; failures or problems in our biometric software products; delays in the adoption of new industry biometric standards; growth of proprietary biometric systems which do not conform to industry s
'/>"/>

SOURCE Aware, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Aware, Inc. Reports Second Quarter 2011 Financial Results
2. Aware, Inc. Reports Second Quarter 2011 Financial Results
3. Aware, Inc. Announces Resignation of Chief Executive Officer
4. Aware, Inc. Reports First Quarter 2011 Financial Results
5. Aware, Inc. Announces Resignation of Chief Executive Officer
6. Aware, Inc. Announces Q4 and FY2010 Earnings Conference Call
7. Aware, Inc. Announces Q4 and FY2010 Earnings Conference Call
8. Aware, Inc. Reports Third Quarter 2010 Financial Results
9. Aware, Inc. Announces Q310 Earnings Conference Call
10. Aware, Inc. Reports Second Quarter 2010 Financial Results
11. Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... to treat tuberculosis could be the basis for a ... fungal infections and parasites, yet evade resistance, according to ... , Led by U. of I. chemistry professor Eric ... SQ109 attacks the tuberculosis bacterium, how the drug can ... malaria and how targeting multiple pathways reduces the ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... per eight hundred births, Down syndrome - or trisomy ... intellectual disability. It results from a chromosomal abnormality where ... chromosome 21 (1% of the human genome). A study ... Department of Genetic Medicine and Development at the University ... Nature , shed light on how the extra chromosome ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... The common fruit fly circling your week-old peach has ... the insect,s eggshell formation. The paradoxical finding gives ... eggshell layer forms as it points to a likely ... biologist in the Medical College of Georgia Schools of ...
... plain with the odd hydrothermal vent, the seafloor appears ... paper being published May 29 in Nature. A ... mid-ocean ridge spreading system, representing potentially the largest surface ... geomicrobiologist Katrina Edwards, the studys corresponding author. While ...
... WEST LAFAYETTE, Ind. - Throughout the overlooked depths of ... important animal is rapidly disappearing. Until recently, the ... was a major food source for commercially important species ... salmon, trout and walleye rely. Scientists are employing ...
Cached Biology News:Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 3'Barren' seafloor teeming with microbial life 2'Barren' seafloor teeming with microbial life 3A Great Lakes mystery: The case of the disappearing species 2A Great Lakes mystery: The case of the disappearing species 3A Great Lakes mystery: The case of the disappearing species 4
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... unique, Rice University-based program that combines a traditional ... undergraduate research internship in nanotechnology, has been awarded ... Heiskell Award for Innovation in International Education. , ... and honor the most outstanding initiatives in international ...
... January 28 Nycomed has granted,Sepracor, Inc. ... marketing and,commercialisation rights for Ciclesonide in the ... a novel principle of action. It,is the ... for the,treatment of asthma and in the ...
... Joseph F. Finn, Jr.,CPA, the Assignee for the Benefit ... of the Company,s fixed assets for in,excess of $300,000 ... to,the high volume of requests for due diligence materials ... the Company has,created an online datasite that allows access ...
Cached Biology Technology:Rice wins innovation award for international program 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6
... (CMV) pp65 Antigenemia Immunofluorescence Assay (IFA) is ... matrix protein pp65 of CMV in isolated ... Erythrocyte Lysis Buffer - ... mL of buffered ammonium chloride. (NH4CL) ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... both 0.2 and 2.0 mL samples for freezing point determinations. Includes built-in ... reading capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: